Dyne Therapeutics (DYN) Research & Development (2019 - 2026)

Dyne Therapeutics (DYN) has reported Research & Development for 8 consecutive years, with $152.2 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Research & Development rose 53.34% year-over-year to $152.2 million; the TTM figure through Jun 2026 stood at $445.7 million (up 17.2% YoY), while the FY2025 annual figure was $398.3 million, up 41.55% from the prior year.
• Research & Development improved to $152.2 million in Q2 2026 per DYN's latest filing, from $100.9 million in the prior quarter.
• Across five years, Research & Development topped out at $152.2 million in Q2 2026 and bottomed at $28.2 million in Q1 2022.
• Historically, Research & Development has averaged $71.5 million across 5 years, with a median of $60.7 million in 2023.
• Annual changes were most pronounced in 2022 — Research & Development retreated 21.54% — and 2025, when it surged 139.0%.
• Dyne Therapeutics' Research & Development stood at $33.2 million in 2022, then surged by 77.29% to $58.8 million in 2023, then surged by 39.02% to $81.8 million in 2024, then advanced by 16.66% to $95.4 million in 2025, then surged by 59.45% to $152.2 million in 2026.
• Business Quant data shows DYN's Research & Development at $152.2 million in Q2 2026, $100.9 million in Q1 2026, and $95.4 million in Q4 2025.